Friends or foes — bipolar effects of the tumour stroma in cancer

Key Points

  • Cancer cells can alter their adjacent stroma to form a permissive and supportive environment for tumour progression — this is known as the 'reactive' tumour stroma.

  • Cancer cells produce a range of growth factors and proteases that modify their stromal environment.

  • These factors disrupt normal tissue homeostasis and act in a paracrine manner to induce angiogenesis and inflammation, as well as activation of surrounding stromal cell types such as fibroblasts, smooth-muscle cells and adipocytes, leading to the secretion of additional growth factors and proteases.

  • Activated fibroblasts in the stroma promote tumour progression by secreting growth factors and pro-migratory extracellular-matrix (ECM) components, as well as upregulating the expression of serine proteases and matrix metalloproteinases that degrade and remodel the ECM.

  • The induction of inflammation in the tumour stroma also results in production of a range of factors that promote tumour progression.

  • Angiogenesis promotes not only tumour growth, but also progression from a pre-malignant to a malignant and invasive tumour phenotype.

  • The tumour stroma can have a more direct role in tumorigenesis, by acting as a mutagen.

  • By 'normalizing' the tumour stroma, it is possible to slow or reverse tumour progression.

Abstract

The restricted view of tumour progression as a multistep process defined by the accumulation of mutations in cancer cells has largely ignored the substantial contribution of the tumour microenvironment to malignancy. Even though the seed and soil hypothesis of Paget dates to 1889, it has been less than two decades since researchers have included the tumour microenvironment in their analyses of tumour progression. What have we recently learned from studying tumour–stroma interactions, and will this help to define new targets for therapy?

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1: Tumour stage depends on stromal activation.
Figure 2: Reversion of tumour phenotype by stromal normalization.
Figure 3: Crosstalk between tumour cells and their activated stromal surroundings.

References

  1. 1

    Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57–70 (2000).

  2. 2

    Paget, S. The distribution of secondary growths in cancer of the breast. Lancet 1, 571–573 (1889).

  3. 3

    Fidler, I. J. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nature Rev. Cancer 3, 453–458 (2003). Summarizes our understanding of tumor–stroma interactions, beginning with Paget's seed and soil hypothesis and leading to the most recent findings on the regulatory mechanisms that determine the potential of tumour cells to metastasize.

  4. 4

    Liotta, L. A. & Kohn, E. C. The microenvironment of the tumour–host interface. Nature 411, 375–379 (2001).

  5. 5

    Dvorak, H. F. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N. Engl. J. Med. 315, 1650–1659 (1986).

  6. 6

    Dvorak, H. F., Senger, D. R. & Dvorak, A. M. Fibrin as a component of the tumor stroma: origins and biological significance. Cancer Metastasis Rev. 2, 41–73 (1983).

  7. 7

    Kuperwasser, C. et al. Reconstruction of functionally normal and malignant human breast tissues in mice. Proc. Natl Acad. Sci. USA 101, 4966–4971 (2004).

  8. 8

    Willis, R. A. in Pathology of Tumors 135–140 (Butterworth, London, 1960).

  9. 9

    Folkman, J. Fundamental concepts of the angiogenic process. Curr. Mol. Med. 3, 643–651 (2003). Comprehensive summary of the development of the field of angiogenesis research over the past three decades, introducing fundamental concepts and describing mechanistic insights recently gained.

  10. 10

    Werner, S. & Grose, R. Regulation of wound healing by growth factors and cytokines. Physiol. Rev. 83, 835–870 (2003).

  11. 11

    Bergers, G. & Benjamin, L. E. Tumorigenesis and the angiogenic switch. Nature Rev. Cancer 3, 401–410 (2003).

  12. 12

    Coussens, L. M. & Werb, Z. Inflammation and cancer. Nature 420, 860–867 (2002). Comprehensive overview of the concept that inflammation is a crucial component of tumour progression.

  13. 13

    De Wever, O. & Mareel, M. Role of tissue stroma in cancer cell invasion. J. Pathol. 200, 429–447 (2003). Reviews the role of fibroblasts as a key component of the tumour microenvironment, their activation and their contribution to tumour growth and progression.

  14. 14

    Manabe, Y., Toda, S., Miyazaki, K. & Sugihara, H. Mature adipocytes, but not preadipocytes, promote the growth of breast carcinoma cells in collagen gel matrix culture through cancer-stromal cell interactions. J. Pathol. 201, 221–228 (2003).

  15. 15

    Mueller, M. M., Werbowetski, T. & Del Maestro, R. F. Soluble factors involved in glioma invasion. Acta Neurochir. (Wien) 145, 999–1008 (2003).

  16. 16

    Stetler-Stevenson, W. G. & Yu, A. E. Proteases in invasion: matrix metalloproteinases. Semin. Cancer Biol. 11, 143–152 (2001).

  17. 17

    Kalluri, R. Basement membranes: structure, assembly and role in tumour angiogenesis. Nature Rev. Cancer 3, 422–433 (2003). Reviews the role of the basement membrane as a crucial component of the tumour microenvironment whose structure and components regulate the process of tumour angiogenesis.

  18. 18

    Brinckerhoff, C. E. & Matrisian, L. M. Matrix metalloproteinases: a tail of a frog that became a prince. Nature Rev. Mol. Cell Biol. 3, 207–214 (2002).

  19. 19

    McCawley, L. J. & Matrisian, L. M. Matrix metalloproteinases: they're not just for matrix anymore! Curr. Opin. Cell Biol. 13, 534–540 (2001).

  20. 20

    Egeblad, M. & Werb, Z. New functions for the matrix metalloproteinases in cancer progression. Nature Rev. Cancer 2, 161–174 (2002).

  21. 21

    Bachmeier, B. E., Boukamp, P., Lichtinghagen, R., Fusenig, N. E. & Fink, E. Matrix metalloproteinases-2,-3,-7,-9 and -10, but not MMP-11, are differentially expressed in normal, benign tumorigenic and malignant human keratinocyte cell lines. Biol. Chem. 381, 497–507 (2000).

  22. 22

    Borchers, A. H. et al. Fibroblast-directed expression and localization of 92-kDa type IV collagenase along the tumor-stroma interface in an in vitro three-dimensional model of human squamous cell carcinoma. Mol. Carcinog. 19, 258–266 (1997).

  23. 23

    Airola, K. & Fusenig, N. E. Differential stromal regulation of MMP-1 expression in benign and malignant keratinocytes. J. Invest. Dermatol. 116, 85–92 (2001).

  24. 24

    Bhowmick, N. A. et al. TGF-β signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 303, 848–851 (2004).

  25. 25

    Weeks, B. H., He, W., Olson, K. L. & Wang, X. J. Inducible expression of transforming growth factor β1 in papillomas causes rapid metastasis. Cancer Res. 61, 7435–7443 (2001).

  26. 26

    Lohr, M. et al. Transforming growth factor-β1 induces desmoplasia in an experimental model of human pancreatic carcinoma. Cancer Res. 61, 550–555 (2001).

  27. 27

    Gabbiani, G., Ryan, G. B. & Majne, G. Presence of modified fibroblasts in granulation tissue and their possible role in wound contraction. Experientia 27, 549–550 (1971).

  28. 28

    Powell, D. W. et al. Myofibroblasts. I. Paracrine cells important in health and disease. Am. J. Physiol. 277, C1–C9 (1999).

  29. 29

    De Wever, O. et al. Tenascin-C and SF/HGF produced by myofibroblasts in vitro provide the convergent proinvasive signals to human colon cancer cells through RhoA and Rac. FASEB J. 18, 1016–1018 (2004).

  30. 30

    Lewis, M. P. et al. Tumour-derived TGF-β1 modulates myofibroblast differentiation and promotes HGF/SF-dependent invasion of squamous carcinoma cells. Br. J. Cancer 90, 822–832 (2004).

  31. 31

    Shao, Z. M., Nguyen, M. & Barsky, S. H. Human breast carcinoma desmoplasia is PDGF initiated. Oncogene 19, 4337–4345 (2000).

  32. 32

    Garin-Chesa, P., Old, L. J. & Rettig, W. J. Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. Proc. Natl Acad. Sci. USA 87, 7235–7239 (1990).

  33. 33

    Lazard, D. et al. Expression of smooth muscle-specific proteins in myoepithelium and stromal myofibroblasts of normal and malignant human breast tissue. Proc. Natl Acad. Sci. USA 90, 999–1003 (1993).

  34. 34

    Park, J. E. et al. Fibroblast activation protein, a dual specificity serine protease expressed in reactive human tumor stromal fibroblasts. J. Biol. Chem. 274, 36505–36512 (1999).

  35. 35

    Chauhan, H. et al. There is more than one kind of myofibroblast: analysis of CD34 expression in benign, in situ, and invasive breast lesions. J. Clin. Pathol. 56, 271–276 (2003).

  36. 36

    Olumi, A. F. et al. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res. 59, 5002–5011 (1999).

  37. 37

    Skobe, M. & Fusenig, N. E. Tumorigenic conversion of immortal human keratinocytes through stromal cell activation. Proc. Natl Acad. Sci. USA 95, 1050–1055 (1998).

  38. 38

    Cunha, G. R., Hayward, S. W., Wang, Y. Z. & Ricke, W. A. Role of the stromal microenvironment in carcinogenesis of the prostate. Int. J. Cancer 107, 1–10 (2003). Discusses the role of stromal–epithelial interactions in normal and malignant prostatic growth and the role that cell–cell interactions and androgen signalling have in determining the malignant phenotype of prostate tumours.

  39. 39

    Sieuwerts, A. M. et al. Urokinase-type-plasminogen-activator (uPA) production by human breast (myo) fibroblasts in vitro: influence of transforming growth factor-β1 (TGFβ1) compared with factor(s) released by human epithelial-carcinoma cells. Int. J. Cancer 76, 829–835 (1998).

  40. 40

    Sato, T. et al. Tumor-stromal cell contact promotes invasion of human uterine cervical carcinoma cells by augmenting the expression and activation of stromal matrix metalloproteinases. Gynecol. Oncol. 92, 47–56 (2004).

  41. 41

    Krtolica, A. & Campisi, J. Integrating epithelial cancer, aging stroma and cellular senescence. Adv. Gerontol. 11, 109–116 (2003).

  42. 42

    Masson, R. et al. in vivo evidence that the stromelysin-3 metalloproteinase contributes in a paracrine manner to epithelial cell malignancy. J. Cell Biol. 140, 1535–1541 (1998).

  43. 43

    Li, G. et al. Function and regulation of melanoma-stromal fibroblast interactions: when seeds meet soil. Oncogene 22, 3162–3171 (2003).

  44. 44

    Orimo, A. et al. Cancer-associated myofibroblasts possess various factors to promote endometrial tumor progression. Clin. Cancer Res. 7, 3097–3105 (2001).

  45. 45

    Balkwill, F. & Mantovani, A. Inflammation and cancer: back to Virchow? Lancet 357, 539–545 (2001).

  46. 46

    Albertsson, P. A. et al. NK cells and the tumour microenvironment: implications for NK-cell function and anti-tumour activity. Trends Immunol. 24, 603–609 (2003).

  47. 47

    Kornfeld, D., Ekbom, A. & Ihre, T. Is there an excess risk for colorectal cancer in patients with ulcerative colitis and concomitant primary sclerosing cholangitis? A population based study. Gut 41, 522–525 (1997).

  48. 48

    Castellsague, X., Bosch, F. X. & Munoz, N. Environmental co-factors in HPV carcinogenesis. Virus Res. 89, 191–199 (2002).

  49. 49

    Nelson, W. G., DeWeese, T. L. & DeMarzo, A. M. The diet, prostate inflammation, and the development of prostate cancer. Cancer Metastasis Rev. 21, 3–16 (2002).

  50. 50

    Martins-Green, M., Boudreau, N. & Bissell, M. J. Inflammation is responsible for the development of wound-induced tumors in chickens infected with Rous sarcoma virus. Cancer Res. 54, 4334–4341 (1994).

  51. 51

    Pollard, J. W. Tumour-educated macrophages promote tumour progression and metastasis. Nature Rev. Cancer 4, 71–78 (2004). Overview of the evidence from clinical and experimental studies that macrophages promote solid-tumour progression and metastasis by adopting a trophic role that facilitates angiogenesis, matrix breakdown and tumour-cell motility — all of which are elements of the metastatic process.

  52. 52

    Leek, R. D. & Harris, A. L. Tumor-associated macrophages in breast cancer. J. Mammary Gland Biol. Neoplasia 7, 177–189 (2002).

  53. 53

    Kacinski, B. M. CSF-1 and its receptor in ovarian, endometrial and breast cancer. Ann. Med. 27, 79–85 (1995).

  54. 54

    Lin, E. Y., Nguyen, A. V., Russell, R. G. & Pollard, J. W. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J. Exp. Med. 193, 727–740 (2001).

  55. 55

    Mueller, M. M. & Fusenig, N. E. Constitutive expression of G-CSF and GM-CSF in human skin carcinoma cells with functional consequence for tumor progression. Int. J. Cancer 83, 780–789 (1999).

  56. 56

    Mueller, M. M. et al. Autocrine growth regulation by granulocyte colony-stimulating factor and granulocyte macrophage colony-stimulating factor in human gliomas with tumor progression. Am. J. Pathol. 155, 1557–1567 (1999).

  57. 57

    Braun, B., Lange, M., Oeckler, R. & Mueller, M. M. Expression of G-CSF and GM-CSF in human meningiomas correlates with increased tumor proliferation and vascularization. J. Neurooncology 68, 131–140 (2004).

  58. 58

    Obermueller, E., Vosseler, S., Fusenig, N. E. & Mueller, M. M. Cooperative auto- and paracrine functions of G-CSF and GM–CSF in the progression of skin carinoma cells. Cancer Res. (in the press).

  59. 59

    DeClerck, Y. A. et al. Proteases, extracellular matrix, and cancer: a workshop of the path B study section. Am. J. Pathol. 164, 1131–1139 (2004).

  60. 60

    Carmeliet, P. & Jain, R. K. Angiogenesis in cancer and other diseases. Nature 407, 249–257 (2000).

  61. 61

    Goldman, E. The growth of malignant disease in man and the lower animals with special reference to the vascular system. Lancet 2, 1236–1240 (1907).

  62. 62

    Black, W. C. & Welch, H. G. Advances in diagnostic imaging and overestimations of disease prevalence and the benefits of therapy. N. Engl. J. Med. 328, 1237–1243 (1993).

  63. 63

    Hanahan, D. & Folkman, J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86, 353–364 (1996).

  64. 64

    Kerbel, R. & Folkman, J. Clinical translation of angiogenesis inhibitors. Nature Rev. Cancer 2, 727–739 (2002). Discusses the role of angiogenesis inhibitors as cancer therapeutics and deals with the questions that are associated with their clinical use and their further optimization.

  65. 65

    Vajkoczy, P. et al. Microtumor growth initiates angiogenic sprouting with simultaneous expression of VEGF, VEGF receptor-2, and angiopoietin-2. J. Clin. Invest. 109, 777–785 (2002).

  66. 66

    Holash, J., Wiegand, S. J. & Yancopoulos, G. D. New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF. Oncogene 18, 5356–5362 (1999).

  67. 67

    Fusenig, N. E. et al. in Proteases and their Inhibitors in Cancer Metastasis (eds Foidart, J. M. & Muschel, R. J.) 205–223 (Kluwer Academic, Dordrecht, The Netherlands, 2002).

  68. 68

    Mueller, M. M. & Fusenig, N. E. Tumor-stroma interactions directing phenotype and progression of epithelial skin tumor cells. Differentiation 70, 486–497 (2002).

  69. 69

    Skobe, M., Rockwell, P., Goldstein, N., Vosseler, S. & Fusenig, N. E. Halting angiogenesis suppresses carcinoma cell invasion. Nature Med. 3, 1222–1227 (1997).

  70. 70

    Smith-McCune, K. K. & Weidner, N. Demonstration and characterization of the angiogenic properties of cervical dysplasia. Cancer Res. 54, 800–804 (1994).

  71. 71

    Clark, E. R. & Clark, E. L. Microscopic observations on the growth of blood capillaries in the living organisms. Am. J. Anat. 64, 251–264 (1938).

  72. 72

    Roskelley, C. D. & Bissell, M. J. The dominance of the microenvironment in breast and ovarian cancer. Semin. Cancer Biol. 12, 97–104 (2002). Summarizes the role of the tumour microenvironment in determining breast cancer phenotypes, with particular emphasis on the suppressive effects of the environment.

  73. 73

    Andriani, F., Garfield, J., Fusenig, N. E. & Garlick, J. A. Basement membrane proteins promote progression of intraepithelial neoplasia in 3-dimensional models of human stratified epithelium. Int. J. Cancer 108, 348–357 (2004).

  74. 74

    Jain, R. K. Molecular regulation of vessel maturation. Nature Med. 9, 685–693 (2003).

  75. 75

    Yang, C. et al. Integrin α1β1 and α2β1 are the key regulators of hepatocarcinoma cell invasion across the fibrotic matrix microenvironment. Cancer Res. 63, 8312–8317 (2003).

  76. 76

    Bleuel, K., Popp, S., Fusenig, N. E., Stanbridge, E. J. & Boukamp, P. Tumor suppression in human skin carcinoma cells by chromosome 15 transfer or thrombospondin-1 overexpression through halted tumor vascularization. Proc. Natl Acad. Sci. USA 96, 2065–2070 (1999).

  77. 77

    Lawler, J. The functions of thrombospondin-1 and-2. Curr. Opin. Cell Biol. 12, 634–640 (2000).

  78. 78

    Lockwood, D. S. et al. Tumor progression in hepatocellular carcinoma: relationship with tumor stroma and parenchymal disease. J. Gastroenterol. Hepatol. 18, 666–672 (2003).

  79. 79

    Bajou, K. et al. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nature Med. 4, 923–928 (1998).

  80. 80

    Noel, A. et al. Membrane associated proteases and their inhibitors in tumour angiogenesis. J. Clin. Pathol. 57, 577–584 (2004). Comprehensive overview on the role of different proteases in ECM degradation — an important mechanism for generating biologically active proteins that regulate processes such as angiogenesis and tumour invasion.

  81. 81

    Cornelius, L. A. et al. Matrix metalloproteinases generate angiostatin: effects on neovascularization. J. Immunol. 161, 6845–6852 (1998).

  82. 82

    Dong, Z., Kumar, R., Yang, X. & Fidler, I. J. Macrophage-derived metalloelastase is responsible for the generation of angiostatin in Lewis lung carcinoma. Cell 88, 801–810 (1997).

  83. 83

    O'Reilly, M. S. et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88, 277–285 (1997).

  84. 84

    Marneros, A. G. & Olsen, B. R. The role of collagen-derived proteolytic fragments in angiogenesis. Matrix Biol. 20, 337–345 (2001).

  85. 85

    Jin, X. et al. Evaluation of endostatin antiangiogenesis gene therapy in vitro and in vivo. Cancer Gene Ther. 8, 982–989 (2001).

  86. 86

    Joki, T. et al. Continuous release of endostatin from microencapsulated engineered cells for tumor therapy. Nature Biotechnol. 19, 35–39 (2001).

  87. 87

    Maeshima, Y. et al. Distinct antitumor properties of a type IV collagen domain derived from basement membrane. J. Biol. Chem. 275, 21340–21348 (2000).

  88. 88

    Sounni, N. E., Janssen, M., Foidart, J. M. & Noel, A. Membrane type-1 matrix metalloproteinase and TIMP-2 in tumor angiogenesis. Matrix Biol. 22, 55–61 (2003).

  89. 89

    Tlsty, T. D. Stromal cells can contribute oncogenic signals. Semin. Cancer Biol. 11, 97–104 (2001). Reviews the transforming effect of stromal cells on epithelial components and provides insights into the possible regulatory mechanisms that underlie the initiation and progression of malignant cells.

  90. 90

    Phillips, J. L. et al. The consequences of chromosomal aneuploidy on gene expression profiles in a cell line model for prostate carcinogenesis. Cancer Res. 61, 8143–8149 (2001).

  91. 91

    Mueller, M. M. et al. Tumor progression of skin carcinoma cells in vivo promoted by clonal selection, mutagenesis, and autocrine growth regulation by granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor. Am. J. Pathol. 159, 1567–1579 (2001).

  92. 92

    Yuan, J. & Glazer, P. M. Mutagenesis induced by the tumor microenvironment. Mutat. Res. 400, 439–446 (1998).

  93. 93

    Jacoby, R. F. et al. A juvenile polyposis tumor suppressor locus at 10q22 is deleted from nonepithelial cells in the lamina propria. Gastroenterology 112, 1398–1403 (1997).

  94. 94

    Moinfar, F. et al. Concurrent and independent genetic alterations in the stromal and epithelial cells of mammary carcinoma: implications for tumorigenesis. Cancer Res. 60, 2562–2566 (2000).

  95. 95

    Haggie, J. A., Sellwood, R. A., Howell, A., Birch, J. M. & Schor, S. L. Fibroblasts from relatives of patients with hereditary breast cancer show fetal-like behaviour in vitro. Lancet 1, 1455–1457 (1987).

  96. 96

    Weaver, V. M. & Gilbert, P. Watch thy neighbor: cancer is a communal affair. J. Cell Sci. 117, 1287–1290 (2004).

  97. 97

    Zhu, Y., Ghosh, P., Charnay, P., Burns, D. K. & Parada, L. F. Neurofibromas in NF1: Schwann cell origin and role of tumor environment. Science 296, 920–922 (2002).

  98. 98

    Billingham, R., Orr, J. & Woodhouse, D. Transplantation of skin components during chemical carcinogenesis with 20-methylcholantrene. Br. J. Cancer 5, 417–432 (1951).

  99. 99

    Barcellos-Hoff, M. H. & Ravani, S. A. Irradiated mammary gland stroma promotes the expression of tumorigenic potential by unirradiated epithelial cells. Cancer Res. 60, 1254–1260 (2000).

  100. 100

    Maffini, M. V., Soto, A. M., Calabro, J. M., Ucci, A. A. & Sonnenschein, C. The stroma as a crucial target in rat mammary gland carcinogenesis. J. Cell Sci. 117, 1495–1502 (2004).

  101. 101

    Illmensee, K. & Mintz, B. Totipotency and normal differentiation of single teratocarcinoma cells cloned by injection into blastocysts. Proc. Natl Acad. Sci. USA 73, 549–553 (1976).

  102. 102

    Weaver, V. M. et al. Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies. J. Cell Biol. 137, 231–245 (1997).

  103. 103

    Vajkoczy, P. et al. Targeting angiogenesis inhibits tumor infiltration and expression of the pro-invasive protein SPARC. Int. J. Cancer 87, 261–268 (2000).

  104. 104

    Sporn, M. B. & Suh, N. Chemoprevention of cancer. Carcinogenesis 21, 525–530 (2000).

  105. 105

    Kerbel, R. S. A cancer therapy resistant to resistance. Nature 390, 335–336 (1997).

  106. 106

    Ricchi, P., Zarrilli, R., Di Palma, A. & Acquaviva, A. M. Nonsteroidal anti-inflammatory drugs in colorectal cancer: from prevention to therapy. Br. J. Cancer 88, 803–807 (2003).

  107. 107

    Salgaller, M. L. Technology evaluation: bevacizumab, Genentech/Roche. Curr. Opin. Mol. Ther. 5, 657–667 (2003).

  108. 108

    Izumi, Y., Xu, L., di Tomaso, E., Fukumura, D. & Jain, R. K. Tumour biology: herceptin acts as an anti-angiogenic cocktail. Nature 416, 279–280 (2002).

  109. 109

    Tan, A. R. & Swain, S. M. Ongoing adjuvant trials with trastuzumab in breast cancer. Semin. Oncol. 30, 54–64 (2003).

  110. 110

    Ferrara, N., Hillan, K. J., Gerber, H. P. & Novotny, W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nature Rev. Drug Discov. 3, 391–400 (2004).

  111. 111

    Sridhar, S. S. & Shepherd, F. A. Targeting angiogenesis: a review of angiogenesis inhibitors in the treatment of lung cancer. Lung Cancer 42 (Suppl. 1), 81–91 (2003).

  112. 112

    Yang, J. C. et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med. 349, 427–434 (2003).

  113. 113

    Koehne, C. H. & Dubois, R. N. COX-2 inhibition and colorectal cancer. Semin. Oncol. 31, 12–21 (2004).

  114. 114

    Goetz, C. et al. Locoregional radioimmunotherapy in selected patients with malignant glioma: experiences, side effects and survival times. J. Neurooncol. 62, 321–328 (2003).

  115. 115

    Tanaka, K., Hiraiwa, N., Hashimoto, H., Yamazaki, Y. & Kusakabe, M. Tenascin-C regulates angiogenesis in tumor through the regulation of vascular endothelial growth factor expression. Int. J. Cancer 108, 31–40 (2004).

  116. 116

    Kalembeyi, I. et al. Tenascin-C upregulates matrix metalloproteinase-9 in breast cancer cells: direct and synergistic effects with transforming growth factor β1. Int. J. Cancer 105, 53–60 (2003).

  117. 117

    Ebbinghaus, C., Scheuermann, J., Neri, D. & Elia, G. Diagnostic and therapeutic applications of recombinant antibodies: targeting the extra-domain B of fibronectin, a marker of tumor angiogenesis. Curr. Pharm. Des. 10, 1537–1549 (2004).

  118. 118

    Reed, C. C., Gauldie, J. & Iozzo, R. V. Suppression of tumorigenicity by adenovirus-mediated gene transfer of decorin. Oncogene 21, 3688–3695 (2002).

  119. 119

    Ichikawa, T. et al. Increased synthesis of hyaluronate enhances motility of human melanoma cells. J. Invest. Dermatol. 113, 935–939 (1999).

  120. 120

    Shuster, S., Frost, G. I., Csoka, A. B., Formby, B. & Stern, R. Hyaluronidase reduces human breast cancer xenografts in SCID mice. Int. J. Cancer 102, 192–197 (2002).

  121. 121

    Mass, R. D. et al. Bevacizumab in combination with 5-FU/leucovorin improves survival in patients with metastatic colorectal cancer: A combined analysis. Proc. Am. Soc. Clin. Oncol. 22, A3616 (2004).

Download references

Acknowledgements

We would like to thank all the co-workers and collaborators who have contributed to his article with their results and their helpful comments and discussions. We apologize to the authors of the numerous papers on this interesting subject who we were unable to quote because of space limitations.

Author information

Correspondence to Norbert E. Fusenig.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Related links

Related links

DATABASES

Entrez Gene

angiopoietin 1

bFGF

CCL2

CSF1

EGFR

G-CSF

GM-CSF

HGF

IGF1

MMP1

MMP13

MMP9

MT1-MMP

PDGF

TGFβ

TSP1

tumour-necrosis factor-α

uPA

VEGF

VEGFR2

National Cancer Institute

breast cancer

cervical cancer

colorectal cancer

prostate cancer

skin cancer

stomach cancer

FURTHER INFORMATION

Angiogenesis Inhibitors in Clinical Trials web site

Epidemiology: Nonsteroidal Anti-Inflammatory Drugs and Cancer Prevention

Special Project Angiogenesis

Glossary

PAGET'S SEED AND SOIL HYPOTHESIS

The English surgeon Stephen Paget compared tumour cells with the seed of plants, in that they are both “carried in all directions; but they can only live and grow if they fall on congenial soil”. Similarly, he argued that metastatic cells must thrive only where conditions are in some way favourable.

TUMOUR STROMA

Compartment providing the connective-tissue framework of the tumour. It includes fibroblasts, immune and inflammatory cells, fat cells and blood-vessel cells.

EXTRACELLULAR MATRIX (ECM)

Complex three-dimensional network of macromolecular protein fibres as well as non-fibrous proteoglycans that is present between clusters of cells in the stroma of all tissues. The ECM provides architectural structure and strength and contextual information for cellular communication, adhesion and migration.

DESMOPLASIA

The growth of fibrous or connective tissue that is induced by tumours and is characterized by activated fibroblasts, recruited inflammatory and immune cells, and angiogenic blood vessels.

ANGIOGENESIS

The formation of new blood vessels from pre-existing ones.

BASEMENT MEMBRANE

Amorphous, dense, sheet-like, proteinaceous structure that is 50–100 nm thick and that separates epithelial and stromal tissues, and delineates the endothelial lining of vessels.

MYOFIBROBLASTS

Activated fibroblasts that express α-smooth-muscle actin, specific growth factors and proteases. They are similar to the carcinoma-associated fibroblasts present in the tumour stroma.

ENDOTHELIAL PROGENITOR CELLS

Undifferentiated cells that reside in the adult bone marrow or circulate in the blood (circulating progenitors) that can be recruited to the sites of ongoing angiogenesis, where they differentiate and mature into endothelial cells. They are identified by co-expression of haematopoietic stem-cell markers (CD34, AC133) and vascular endothelial cell markers (VEGFR2, TIE2)

ANGIOGENIC SWITCH

Transition of tumours from an avascular state to the active recruitment of blood vessels into the tumour.

HEMISDESMOSOME

Specialized junction between an epithelial cell and its basal lamina that mediates their interactions.

PERINEURAL CELLS

The outermost layer of stromal cells that surround peripheral nerves.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Mueller, M., Fusenig, N. Friends or foes — bipolar effects of the tumour stroma in cancer. Nat Rev Cancer 4, 839–849 (2004). https://doi.org/10.1038/nrc1477

Download citation

Further reading